Neuropsychiatric	B:C4285807
symptoms	I:C4285807
in	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
:	O
impact	O
on	O
quality	O
of	O
life	O
.	O

Neuropsychiatric	O
symptoms	I:C4285807
in	O
systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
:	O
impact	O
on	O
quality	O
of	O
life	O
.	O

Objective	B:C0018017
Assess	O
quality	O
of	O
life	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
(	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
)	O
presenting	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
(	O
neuropsychiatric	O
SLE	I:C0752335
,	O
NPSLE	O
)	O
.	O

Objective	O
Assess	O
quality	O
of	O
life	O
in	O
patients	O
with	O
systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
(	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
)	O
presenting	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
(	O
neuropsychiatric	O
SLE	I:C0752335
,	O
NPSLE	O
)	O
.	O

Objective	O
Assess	O
quality	O
of	O
life	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
(	O
systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
)	O
presenting	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
(	O
neuropsychiatric	O
SLE	I:C0752335
,	O
NPSLE	O
)	O
.	O

Objective	O
Assess	O
quality	O
of	O
life	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
(	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
)	O
presenting	O
with	O
neuropsychiatric	B:C4285807
symptoms	I:C4285807
(	O
neuropsychiatric	O
SLE	I:C0752335
,	O
NPSLE	O
)	O
.	O

Objective	O
Assess	O
quality	O
of	O
life	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
(	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
)	O
presenting	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
(	O
neuropsychiatric	B:C0752335
SLE	I:C0752335
,	O
NPSLE	O
)	O
.	O

Objective	O
Assess	O
quality	O
of	O
life	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
(	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
)	O
presenting	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
(	O
neuropsychiatric	O
SLE	I:C0752335
,	O
NPSLE	B:C0752335
)	O
.	O

Methods	B:C0025663
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	O
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	O
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	O
the	O
Leiden	O
NPSLE	O
clinic	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Methods	O
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	B:C1519136
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	O
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	O
the	O
Leiden	O
NPSLE	O
clinic	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Methods	O
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	O
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	B:C1519136
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	O
the	O
Leiden	O
NPSLE	O
clinic	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Methods	O
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	O
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	O
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	B:C1512346
the	O
Leiden	O
NPSLE	O
clinic	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Methods	O
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	O
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	O
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	O
the	O
Leiden	B:C0017446
NPSLE	O
clinic	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Methods	O
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	O
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	O
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	O
the	O
Leiden	O
NPSLE	B:C0752335
clinic	O
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Methods	O
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	O
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	O
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	O
the	O
Leiden	O
NPSLE	O
clinic	B:C0442592
at	O
baseline	O
and	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
.	O

Methods	O
Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Short	O
-	I:C1519136
Form	I:C1519136
36	I:C1519136
item	I:C1519136
Health	I:C1519136
Survey	I:C1519136
(	O
SF	O
-	I:C1519136
36	I:C1519136
)	O
in	O
patients	O
visiting	O
the	O
Leiden	O
NPSLE	O
clinic	O
at	O
baseline	O
and	O
at	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
.	O

SF	B:C1519136
-	I:C1519136
36	I:C1519136
subscales	O
and	O
summary	O
scores	O
were	O
calculated	O
and	O
compared	O
with	O
quality	O
of	O
life	O
of	O
the	O
general	O
Dutch	O
population	I:C0013331
and	O
patients	O
with	O
other	O
chronic	O
diseases	I:C0008679
.	O

SF	O
-	I:C1519136
36	I:C1519136
subscales	O
and	O
summary	O
scores	O
were	O
calculated	O
and	O
compared	O
with	O
quality	O
of	O
life	O
of	O
the	O
general	B:C0205246
Dutch	O
population	I:C0013331
and	O
patients	O
with	O
other	O
chronic	O
diseases	I:C0008679
.	O

SF	O
-	I:C1519136
36	I:C1519136
subscales	O
and	O
summary	O
scores	O
were	O
calculated	O
and	O
compared	O
with	O
quality	O
of	O
life	O
of	O
the	O
general	O
Dutch	B:C0013331
population	I:C0013331
and	O
patients	O
with	O
other	O
chronic	O
diseases	I:C0008679
.	O

SF	O
-	I:C1519136
36	I:C1519136
subscales	O
and	O
summary	O
scores	O
were	O
calculated	O
and	O
compared	O
with	O
quality	O
of	O
life	O
of	O
the	O
general	O
Dutch	O
population	I:C0013331
and	O
patients	O
with	O
other	O
chronic	B:C0008679
diseases	I:C0008679
.	O

At	O
baseline	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
in	O
248	O
systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
patients	O
,	O
of	O
whom	O
98	O
had	O
NPSLE	O
(	O
39.7	O
%	O
)	O
.	O

At	O
baseline	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
in	O
248	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
patients	O
,	O
of	O
whom	O
98	O
had	O
NPSLE	B:C0752335
(	O
39.7	O
%	O
)	O
.	O

Follow	B:C1522577
-	I:C1522577
up	I:C1522577
data	O
were	O
available	O
for	O
104	O
patients	O
(	O
42	O
%	O
)	O
,	O
of	O
whom	O
64	O
had	O
NPSLE	O
(	O
61.5	O
%	O
)	O
.	O

Follow	O
-	I:C1522577
up	I:C1522577
data	O
were	O
available	O
for	O
104	O
patients	O
(	O
42	O
%	O
)	O
,	O
of	O
whom	O
64	O
had	O
NPSLE	B:C0752335
(	O
61.5	O
%	O
)	O
.	O

systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
patients	O
presenting	O
neuropsychiatric	O
symptoms	I:C4285807
showed	O
a	O
significantly	O
reduced	O
quality	O
of	O
life	O
in	O
all	O
subscales	O
of	O
the	O
SF	O
-	I:C1519136
36	I:C1519136
.	O

systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
patients	O
presenting	O
neuropsychiatric	B:C4285807
symptoms	I:C4285807
showed	O
a	O
significantly	O
reduced	O
quality	O
of	O
life	O
in	O
all	O
subscales	O
of	O
the	O
SF	O
-	I:C1519136
36	I:C1519136
.	O

systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
patients	O
presenting	O
neuropsychiatric	O
symptoms	I:C4285807
showed	O
a	O
significantly	O
reduced	O
quality	O
of	O
life	O
in	O
all	O
subscales	O
of	O
the	O
SF	B:C1519136
-	I:C1519136
36	I:C1519136
.	O

Quality	O
of	O
life	O
at	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
showed	O
a	O
significant	O
improvement	O
in	O
physical	O
functioning	I:C0516981
role	O
(	O
p	O
=	O
0.001	O
)	O
,	O
social	O
functioning	O
(	O
p	O
=	O
0.007	O
)	O
,	O
vitality	O
(	O
p	O
=	O
0.023	O
)	O
,	O
mental	O
health	I:C0025353
(	O
p	O
=	O
0.014	O
)	O
and	O
mental	O
component	O
score	O
(	O
p	O
=	O
0.042	O
)	O
in	O
patients	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
not	O
attributed	O
to	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
,	O
but	O
no	O
significant	O
improvement	O
was	O
seen	O
in	O
patients	O
with	O
NPSLE	O
.	O

Quality	O
of	O
life	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
showed	O
a	O
significant	O
improvement	O
in	O
physical	B:C0516981
functioning	I:C0516981
role	O
(	O
p	O
=	O
0.001	O
)	O
,	O
social	O
functioning	O
(	O
p	O
=	O
0.007	O
)	O
,	O
vitality	O
(	O
p	O
=	O
0.023	O
)	O
,	O
mental	O
health	I:C0025353
(	O
p	O
=	O
0.014	O
)	O
and	O
mental	O
component	O
score	O
(	O
p	O
=	O
0.042	O
)	O
in	O
patients	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
not	O
attributed	O
to	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
,	O
but	O
no	O
significant	O
improvement	O
was	O
seen	O
in	O
patients	O
with	O
NPSLE	O
.	O

Quality	O
of	O
life	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
showed	O
a	O
significant	O
improvement	O
in	O
physical	O
functioning	I:C0516981
role	O
(	O
p	O
=	O
0.001	O
)	O
,	O
social	O
functioning	O
(	O
p	O
=	O
0.007	O
)	O
,	O
vitality	B:C0424589
(	O
p	O
=	O
0.023	O
)	O
,	O
mental	O
health	I:C0025353
(	O
p	O
=	O
0.014	O
)	O
and	O
mental	O
component	O
score	O
(	O
p	O
=	O
0.042	O
)	O
in	O
patients	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
not	O
attributed	O
to	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
,	O
but	O
no	O
significant	O
improvement	O
was	O
seen	O
in	O
patients	O
with	O
NPSLE	O
.	O

Quality	O
of	O
life	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
showed	O
a	O
significant	O
improvement	O
in	O
physical	O
functioning	I:C0516981
role	O
(	O
p	O
=	O
0.001	O
)	O
,	O
social	O
functioning	O
(	O
p	O
=	O
0.007	O
)	O
,	O
vitality	O
(	O
p	O
=	O
0.023	O
)	O
,	O
mental	B:C0025353
health	I:C0025353
(	O
p	O
=	O
0.014	O
)	O
and	O
mental	O
component	O
score	O
(	O
p	O
=	O
0.042	O
)	O
in	O
patients	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
not	O
attributed	O
to	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
,	O
but	O
no	O
significant	O
improvement	O
was	O
seen	O
in	O
patients	O
with	O
NPSLE	O
.	O

Quality	O
of	O
life	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
showed	O
a	O
significant	O
improvement	O
in	O
physical	O
functioning	I:C0516981
role	O
(	O
p	O
=	O
0.001	O
)	O
,	O
social	O
functioning	O
(	O
p	O
=	O
0.007	O
)	O
,	O
vitality	O
(	O
p	O
=	O
0.023	O
)	O
,	O
mental	O
health	I:C0025353
(	O
p	O
=	O
0.014	O
)	O
and	O
mental	O
component	O
score	O
(	O
p	O
=	O
0.042	O
)	O
in	O
patients	O
with	O
neuropsychiatric	B:C4285807
symptoms	I:C4285807
not	O
attributed	O
to	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
,	O
but	O
no	O
significant	O
improvement	O
was	O
seen	O
in	O
patients	O
with	O
NPSLE	O
.	O

Quality	O
of	O
life	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
showed	O
a	O
significant	O
improvement	O
in	O
physical	O
functioning	I:C0516981
role	O
(	O
p	O
=	O
0.001	O
)	O
,	O
social	O
functioning	O
(	O
p	O
=	O
0.007	O
)	O
,	O
vitality	O
(	O
p	O
=	O
0.023	O
)	O
,	O
mental	O
health	I:C0025353
(	O
p	O
=	O
0.014	O
)	O
and	O
mental	O
component	O
score	O
(	O
p	O
=	O
0.042	O
)	O
in	O
patients	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
not	O
attributed	O
to	O
systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
,	O
but	O
no	O
significant	O
improvement	O
was	O
seen	O
in	O
patients	O
with	O
NPSLE	O
.	O

Quality	O
of	O
life	O
at	O
follow	O
-	I:C1522577
up	I:C1522577
showed	O
a	O
significant	O
improvement	O
in	O
physical	O
functioning	I:C0516981
role	O
(	O
p	O
=	O
0.001	O
)	O
,	O
social	O
functioning	O
(	O
p	O
=	O
0.007	O
)	O
,	O
vitality	O
(	O
p	O
=	O
0.023	O
)	O
,	O
mental	O
health	I:C0025353
(	O
p	O
=	O
0.014	O
)	O
and	O
mental	O
component	O
score	O
(	O
p	O
=	O
0.042	O
)	O
in	O
patients	O
with	O
neuropsychiatric	O
symptoms	I:C4285807
not	O
attributed	O
to	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
,	O
but	O
no	O
significant	O
improvement	O
was	O
seen	O
in	O
patients	O
with	O
NPSLE	B:C0752335
.	O

Conclusion	O
Quality	O
of	O
life	O
is	O
significantly	O
reduced	O
in	O
patients	O
with	O
systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
presenting	O
neuropsychiatric	O
symptoms	I:C4285807
compared	O
with	O
the	O
general	O
population	I:C0683971
and	O
patients	O
with	O
other	O
chronic	O
diseases	I:C0008679
.	O

Conclusion	O
Quality	O
of	O
life	O
is	O
significantly	O
reduced	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
presenting	O
neuropsychiatric	B:C4285807
symptoms	I:C4285807
compared	O
with	O
the	O
general	O
population	I:C0683971
and	O
patients	O
with	O
other	O
chronic	O
diseases	I:C0008679
.	O

Conclusion	O
Quality	O
of	O
life	O
is	O
significantly	O
reduced	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
presenting	O
neuropsychiatric	O
symptoms	I:C4285807
compared	O
with	O
the	O
general	B:C0683971
population	I:C0683971
and	O
patients	O
with	O
other	O
chronic	O
diseases	I:C0008679
.	O

Conclusion	O
Quality	O
of	O
life	O
is	O
significantly	O
reduced	O
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
presenting	O
neuropsychiatric	O
symptoms	I:C4285807
compared	O
with	O
the	O
general	O
population	I:C0683971
and	O
patients	O
with	O
other	O
chronic	B:C0008679
diseases	I:C0008679
.	O

Quality	O
of	O
life	O
remains	O
considerably	O
impaired	O
at	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
.	O

Our	O
results	O
illustrate	O
the	O
need	O
for	O
biopsychosocial	B:C2958078
care	I:C2958078
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
and	O
neuropsychiatric	O
symptoms	I:C4285807
.	O

Our	O
results	O
illustrate	O
the	O
need	O
for	O
biopsychosocial	O
care	I:C2958078
in	O
patients	O
with	O
systemic	B:C0024141
lupus	I:C0024141
erythematosus	I:C0024141
and	O
neuropsychiatric	O
symptoms	I:C4285807
.	O

Our	O
results	O
illustrate	O
the	O
need	O
for	O
biopsychosocial	O
care	I:C2958078
in	O
patients	O
with	O
systemic	O
lupus	I:C0024141
erythematosus	I:C0024141
and	O
neuropsychiatric	B:C4285807
symptoms	I:C4285807
.	O

